Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
JERSEY, Channel Islands, Oct. 17, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2017, will be released after market close on Monday, October 30, 2017.
Quotient will host a conference call on Tuesday, October 31, 2017 at 8:30 a.m. Eastern Time to discuss its fiscal second quarter 2018 financial results. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The conference call will be webcast live on the Company's website at www.quotientbd.com.
A replay of this conference call will be available through November 7, 2017 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13672301.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Christopher Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
